ArticleNutrition & metabolism2025
Adherence to life's essential 8 and progression trajectory of cardiometabolic multimorbidity: a prospective cohort study.
Article in Nutrition & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glycemic Markers and Cardiometabolic Multiple Long-Term Conditions: Comparative Roles of Glycated Hemoglobin and Fasting Plasma Glucose in the English Longitudinal Study of Ageing.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- LIFE's essential 8: a roadmap for preventing cardiometabolic disease progression.Nutrition & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe Life's Essential 8 (LE8) score, developed by the American Heart Association to evaluate cardiovascular health (CVH), was recently updated. Few studies have explored its effect on the incidence, progression, and prognosis of cardiometabolic multimorbidity (CMM). This study examines the association between the LE8 and the progress of CMM.
methodsThis prospective cohort study included 264,597 participants from the UK Biobank. CMM was defined as the presence of at least two of the three cardiometabolic diseases (CMDs): type 2 diabetes (T2D), stroke, and ischemic heart disease (IHD). Multi-state models were employed to investigate the relationship between the LE8 score and its subscales with risk of transitions from healthy to the onset of first cardiometabolic diseases (FCMD), followed by progression to CMM and to death.
resultsOver a median follow-up of 13.94 years, 33,868 individuals developed at least one CMD, 4282 were diagnosed with CMM, and 4955 died. The results indicated that for each 1-SD increase in the LE8 score, a notable reduction was observed in the rate of progression from baseline to FCMD, baseline to death, and FCMD to CMM, with hazard ratios (HRs) of 0.64 (95% CI: 0.63, 0.65), 0.83 (95% CI: 0.81, 0.85), and 0.80 (95% CI: 0.78, 0.83), respectively. However, no correlation was found between the LE8 score and the transition from FCMD or CMM to death. By contrast, per 1-SD increment in the behavior scale score was associated with decreased risk of transition from FCMD to death (HR: 0.93; 95% CI: 0.90, 0.95) and from CMM to death (HR: 0.89; 95% CI: 0.88, 0.95), while per 1-SD increment in the biological scale score was associated with increased risk of transition from FCMD to death (HR: 1.10; 95% CI: 1.07, 1.14), and from CMM to death (HR: 1.22; 95% CI: 1.15, 1.29).
conclusionThe LE8 defined CVH influences the progression from a healthy state to FCMD, CMM, and death, highlighting the importance of improving CVH as a comprehensive approach for preventing CMM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.